SCHEMBL7515776

SCHEMBL7515776

COc1cc2ncnc(Cc3cccc(C(F)(F)F)c3)c2cc1OC

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 11/20 0.58
ABCG2 Q9UNQ0 1/20 0.58
CSF1R P07333 3/20 0.57
BRAF P15056 3/20 0.48
KDR P35968 3/20 0.48
MAPK14 Q16539 1/20 0.48
TNNI3K Q59H18 1/20 0.48
KIT P10721 2/20 0.47
HTR1A P08908 1/20 0.46
HTR7 P34969 1/20 0.46
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
LCK P06239 1/20 0.46
ERBB2 P04626 1/20 0.45
RET P07949 1/20 0.45
FGFR4 P22455 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7517324 0.86 KIT (0.60) EGFRABCG2CSF1RBRAFKDR
SCHEMBL6183340 0.82 EGFR (0.61) EGFRCSF1RKDRKITHTT
SCHEMBL6273407 0.81 EGFR (0.57) EGFRABCG2CSF1RKDRMAPK14
SCHEMBL16585401 0.81 MAPK1 (0.65) EGFRCSF1RMAPK14HTTKDM4E
SCHEMBL8708372 0.81 EGFR (0.67) EGFRABCG2CSF1RBRAFKDR
Hydrochloric Acid SCHEMBL8503039 0.80 EGFR (0.66) EGFRABCG2CSF1RBRAFKDR
SCHEMBL7512207 0.79 MAPK1 (0.62) EGFRABCG2CSF1RHTTKDM4E
SCHEMBL7512753 0.79 KIT (0.62) EGFRABCG2CSF1RKITHTT
SCHEMBL19792401 0.76 KDM4E (0.62) EGFRCSF1RKDRKITHTT
SCHEMBL7516352 0.75 MAPK1 (0.51) EGFRCSF1RKDRHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0832073-B1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN INC (US) 2002-01-16 EP claimed
EP-0832073-B1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN INC (US) 2002-01-16 EP disclosed
US-6103728-A MODULATING TYROSINE SIGNAL TRANSDUCTION TO PREVENT AND TREAT CELL PROLIFERATIVE DISORDERS OR CELL DIFFERENTIATION DISORDERS BY INHIBITING ONE OR MORE ABNORMAL TYROSINE KINASE ACTIVITIES; ANTICARCINOGENIC,-TUMOR, PROLIFERATIVE AGENTS SUGEN, INC. (US) 2000-08-15 US disclosed
EP-0832073-A1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS Sugen, Inc. (US) 1998-04-01 EP disclosed
WO-1996040648-A1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN, INC. (US) 1996-12-19 WO disclosed